Preparation and characterization of spironolactone-loaded nano-emulsions for extemporaneous applications

International Journal of Pharmaceutics

Volumn 478, Issue 1, 2015, Pages 193-201

  Hallouard, François ^a   Dollo, Gilles ^a,b   Brandhonneur, Nolwenn ^a   Grasset, Fabien ^a,c   Corre, Pascal Le ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

Nano emulsions; Nasogastric tube; Spironolactone; Spontaneous surfactant diffusion; Swallowing difficulty

Indexed keywords

AMPHOPHILE; NONIONIC SURFACTANT; SPIRONOLACTONE; EMULSION; NANOPARTICLE; OIL; SURFACTANT;

ARTICLE; DIFFUSION; EMULSION; HYDRODYNAMICS; HYDROPHOBICITY; NANOEMULSION; OSMOLARITY; PH; PHARMACY; SOLUBILITY; ULTRAVIOLET SPECTROPHOTOMETRY; VISCOSITY; ZETA POTENTIAL; CHEMISTRY; DIGESTIVE TRACT INTUBATION; DRUG STABILITY;

DRUG STABILITY; EMULSIONS; INTUBATION, GASTROINTESTINAL; NANOPARTICLES; OILS; SOLUBILITY; SPIRONOLACTONE; SURFACE-ACTIVE AGENTS; VISCOSITY;

EID: 84911901977     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.11.046     Document Type: Article

References (36)

1. Afssaps, 2011. Bonnes Pratiques de Préparation.
2. Agence nationale de sécurité du médicament et des produits de santé (ANSM), 2014. Licenced medicines containing spironolactone and commercialized in France (Base de donnée publique des médicaments).
3. L.V. Allen, and M.A. Erickson Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids Am. J. Health Syst. Pharm. 53 1996 2304 2309
4. N. Anton, J.P. Benoit, and P. Saulnier Design and production of nanoparticles formulated from nano-emulsion templates - a review J Control. Release 128 2008 185 199
5. S.A. Atkinson, J.K. Shah, C. McGee, and B.T. Steele Mineral excretion in premature infants receiving various diuretic therapies J. Pediatr. 113 1988 540 545
6. N. Bernal, A. Calpena, M. Mallandrich, A. Ruiz, and B. Clares Development, physical-chemical stability, and release studies of four alcohol-free spironolactone suspensions for use in pediatrics Dissolut. Technol. 21 2014 19 30
7. G. Broughton, and L. Squires The viscosity of oil-water emulsions J. Phys. Chem. 42 1938 253 263
8. J.M. Clarke, L.E. Ramsay, J.R. Shelton, M.J. Tidd, S. Murray, and R.F. Palmer Factors influencing comparative bioavailability of spironolactone tablets J. Pharm. Sci. 66 1977 1429 1432
9. P. Couvreur, G. Barratt, E. Fattal, P. Legrand, and C. Vauthier Nanocapsule technology: a review Crit. Rev. Ther. Drug Carr. Syst. 19 2002 99 134
10. Y. Dong, W.K. Ng, S. Shen, S. Kim, and R.B.H. Tan Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation Int. J. Pharm. 375 2009 84 88
11. European Directorate for the Quality of Medicines & HealthCare (EDQM), 2014. Spironolactone monograph, in: European Pharmacopoeia.
12. M.N. Fransson, H. Gréen, J.-E. Litton, and L.E. Friberg Influence of cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and Its metabolites using a mechanism-based model Drug Metab. Dispos. 39 2011 247 255
13. Gattefossé SA, 2010. Technical Data Sheets (TDS) of Labrafil M 1944CS.
14. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
15. F. Hallouard Formulation de nano-particules iodées comme agents de contraste a longue rémanence vasculaire pour tomodensitométrie (PhD thesis) 2012 Lyon I Lyon
16. F. Hallouard, N. Anton, G. Zuber, P. Choquet, Y. Arntz, G. Aubertin, A. Constantinesco, and T. Vandamme Radiopaque iodinated nano-emulsions for preclinical X-ray imaging applications RSC Adv. 1 2011 792 801
17. F. Hallouard, S. Briançon, N. Anton, X. Li, T. Vandamme, and H. Fessi Iodinated nano-emulsions as contrast agents for preclinical X-ray imaging, impact of the free surfactants on the pharmacokinetics Eur. J. Pharm. Biopharm. 83 2013 54 62
18. A.M. Kaukonen, I. Kilpeläinen, and J.-P. Mannermaa Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: solubilization and stability of spironolactone in solutions of β-cyclodextrin derivatives Int. J. Pharm. 159 1997 159 170
19. A. Laouini, C. Jaafar-Maalej, S. Sfar, C. Charcosset, and H. Fessi Liposome preparation using a hollow fiber membrane contactor - application to spironolactone encapsulation Int. J. Pharm. 415 2011 53 61
20. R.D. Leff, and R.J. Roberts Problems in drug therapy for pediatric patients Am. J. Hosp. Pharm. 44 1987 865 870
21. G. Levy Availability of spironolactone given by mouth Lancet 280 1962 723 724
22. I. Limayem Blouza, C. Charcosset, S. Sfar, and H. Fessi Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use Int. J. Pharm. 325 2006 124 131
23. X. Li, N. Anton, G. Zuber, M. Zhao, N. Messaddeq, F. Hallouard, F. Hatem, and T. Vandamme Iodinated alpha-tocopherol nano-emulsions: an efficient new non-toxic contrast agent for preclinical X-ray imaging Biomaterials 34 2013 481 491
24. X. Li, Y. Yue, Y. Zhou, Y. Fan, C. Fan, F. Huang, F. Wu, and Y. Liu An oil-free microemulsion for intravenous delivery of diallyl trisulfide: formulation and evaluation Int. J. Pharm. 2011 158 166
25. L.K. Mathur, and A. Wickman Stability of extemporaneously compounded spironolactone suspensions Am. J. Hosp. Pharm. 46 1989 2040 2042
26. M.C. Nahata, R.S. Morosco, and T.F. Hipple Stability of spironolactone in an extemporaneously prepared suspension at two temperatures Ann. Pharmacother. 27 1993 1198 1199
27. PharmInfoTech Spironolactone Formulation in Pharmacy Practice 2001 PharmInfoTech
28. Y. Pramar, V. Das Gupta, and C. Bethea Development of a stable oral liquid dosage form of spironolactone J. Clin. Pharm. Ther. 17 1992 245 248
29. D. Quintanar-Guerrero, H. Fessi, E. Allémann, and E. Doelker Influence of stabilizing agents and preparative variables on the formation of poly(d,l-lactic acid) nanoparticles by an emulsification-diffusion technique Int. J. Pharm. 143 1996 133 141
30. R.C. Rowe, P.J. Sheskey, and M.E. Quinn Polyoxyethylene castor oil derivatives Handbook of Pharmaceutical Excipients 2009 Pharmaceutical Press 542 549
31. O.A.E. Soliman, K. Kimura, F. Hirayama, K. Uekama, H.M. El-Sabbagh, A.E.-G.H.A. El-Gawad, and F.M. Hashim Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability Int. J. Pharm. 149 1997 73 83
32. J. Standing, and F. Tuleu Paediatric formulations - getting to the heart of the problem Int. J. Pharm. 300 2005 56 66
33. J.L. Sutter, and E.P.K. Lau Spironolactone Klaus Florey Analytical Profiles of Drug Substances 1975 Academic Press 431 451
34. S.C. Sweetman Spironolactone monograph Martindale the Complete Drug Reference 2009 Pharmaceutical Press 1400-1402
35. C.K. Taketomo Pediatric & Neonatal Dosage Handbook With International Trade Names Index 18th Revised edition 2012 Lexi-Comp Hudson, Ohio, U.S
36. G. Zhao, J. Huang, K. Xue, L. Si, and G. Li Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition Eur. J. Pharm. Sci. 50 2013 429 439